Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Avatar Builder  |  Contact Info  |  Update Email  |  Update Password  |  Leaderboards  |  Manage Favourite  |  Reputation  |  Reputation History  |  Subscriptions  |  Payment Info  |  Invoices  |  Favourites

Bullboard Post History

by CancerSlayer

V.TLT

A Better Vaccine Approach For Our Tech?

An intranasal &/or inhaled approach that offers both mucosal &...

June 18, 2022

V.TLT

RE:Urgent need for vaccine against COVID variants:

There seems to be waning long-term protective immunity with repeated boosting...

June 18, 2022

V.TLT

RE:A Revisit Of Trial Results From AUA…

CancerSlayer wrote: Feb. 2022 Table. Clinical trial results for...

June 17, 2022

V.HPQ

RE:Brutal

Snowdogy wrote: The whole market is taking it in the ear but its a good time...

June 16, 2022

V.TLT

RE:RE:RE:RE:Not long until the AGM

Jaro1977 wrote: If they take questions at the AGM, what would you be asking? ...

June 16, 2022

V.TLT

A Revisit Of Trial Results From AUA…

Feb. 2022 Table. Clinical trial results for novel agents in patients...

June 16, 2022

V.TLT

RE:Nap time

and south...

June 16, 2022

C.COOL

RE:Core One mgmt, get on with it

lscfa wrote: Demand for psilocybin is there so start competing with its...

June 16, 2022

C.COOL

RE:Takeover

A buyout appears to be their objective & only chance at the moment.  ...

June 16, 2022

V.TLT

RE:RE:RE:N-803 median duration of response

Hi Enrique...long time no see. I agree with your NR description.  I...

June 15, 2022

V.TLT

RE:N-803 median duration of response

Eoganacht wrote: ImmunityBio has concluded their Quilt 3.032 trial of N-803...

June 14, 2022

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Deliberate Obfuscation

Imo, we don't need to beat N-803 + BCG.  The severe lack of...

June 13, 2022

V.TLT

RE:Time for some good news.

Infinity wrote: I am hoping that the management would do something to bring...

June 13, 2022

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Deliberate Obfuscation

Imo, we don't need "best" results...great if we get them, but...

June 13, 2022

V.TLT

RE:RE:Deliberate Obfuscation

langosta wrote: Ah Scorp we are all speculating here. I try to understand...

June 11, 2022

V.TLT

RE:RE:The Forgotten Chart…

  Hi Pandora....It would be helpful to get clarification on how the...

June 11, 2022

V.TLT

RE:I have well over 2M of shares + options

Marco321 wrote: ...and I have been around for I guess over 5 years. We are...

June 11, 2022

V.TLT

The Forgotten Chart…

From May 30 MD&A.... Just looking at the 450 day data for all ...

June 11, 2022

V.TLT

RE:RE:RE:Durable Response

Hi Eoganacht... Maybe you can clarify the discrepancy I'm seeing in...

June 10, 2022

V.TLT

RE:Durable Response

  Thanks Eoganacht... Here's a comparison looking at 450 day...

June 10, 2022

Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next

Featured Company

Innocan Pharma Corp

Innocan Pharma Corp C.INNO

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the ... view more »